GC Biopharma USA, Inc., a leader in plasma-derived products, announced today that it will host a lunch symposium and support ...

Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patientsOSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE ...

It is the first targeted treatment for gMG to be cleared for NHS use in England, after two others – Argenx's Vyvgart (efgartigimod) and UCB's Zilbrysq (zilucoplan) – were deemed not to be ...

Q1 2026 Earnings Call May 6, 2026 4:30 PM EDTCompany ParticipantsAdam Grossman - Co-Founder, President, CEO & DirectorP.

IVIG may reduce seizure frequency in some children with drug-resistant epilepsy, especially those with generalized seizures.

Biologic medications, administered by infusion, can help induce and maintain remission in people with Crohn’s disease by targeting specific proteins that drive inflammation. Prior to receiving a Crohn ...

Label expansion enables serotype-agnostic use of FcRn blockade in adult gMG, positioning both IV Vyvgart and SC Vyvgart Hytrulo as first approved options regardless of antibody status. ADAPT SERON ...

Fabry disease is an X-linked disorder of glycosphingolipid accumulation, caused by α-galactosidase A (α-Gal A) deficiency and associated with renal dysfunction. Clinic-based supplementation with ...